



LIBRARIES
UNIVERSITY OF WISCONSIN - MADISON

Hycotuss advertisement.

[s.l.]: [s.n.], 1979

<https://digital.library.wisc.edu/1711.dl/IEX5D6VTF5JPT8C>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.

HYCOTUSS[®] EXPECTORANT

Each teaspoonful (5 ml) contains 5 mg hydrocodone bitartrate (WARNING: May be habit forming), 100 mg guaifenesin and alcohol U.S.P. 10% v/v



CONTROLS THE HAUNTING COUGH

HYCOTUSS Expectorant combines the proven efficacy of hydrocodone with the known expectorant action of guaifenesin to control unproductive coughs. Whether the cough is associated with upper or lower respiratory tract congestion, effective cough relief is provided and lasts for up to 6 hours.

HYCOTUSS Expectorant. When it comes to cough relief for children under 12, you couldn't ask for more.

USUAL DOSAGE: *Children under 2 years*—calculate as hydrocodone, 0.3 mg/kg/24 hours, divided into 4 equal doses.
Children 2 to 12 years—½ teaspoonful after meals and at bedtime, not less than 4 hours apart.
Children over 12 and adults—1 teaspoonful after meals and at bedtime, not less than 4 hours apart.
Please see brief summary of prescribing information below.

BRIEF SUMMARY OF PRESCRIBING INFORMATION

CONTRAINDICATIONS: HYCOTUSS Expectorant should not be used in patients with hypersensitivity to hydrocodone or guaifenesin.

WARNINGS: HYCOTUSS Expectorant should be prescribed and administered with the same degree of caution appropriate for the use of other oral narcotic-containing medications since it can produce drug dependence and, therefore, has the potential for abuse. Patients should be warned not to drive a car or operate machinery if they become drowsy or show impaired mental and/or physical abilities while taking HYCOTUSS Expectorant. Patients receiving narcotic analgesics, phenothiazines, other tranquilizers, sedative-hypnotics or other central nervous system depressants (including alcohol) concomitantly with HYCOTUSS Expectorant may exhibit an additive central nervous system depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced.

PRECAUTIONS: Before prescribing medication to suppress or modify cough, it is important to ascertain that the underlying cause of cough is identified, that modification of cough does not increase the risk of clinical or physiologic complications, and that appropriate therapy for the primary disease is provided.

ADVERSE REACTIONS: Adverse reactions, when they occur, include sedation, nausea, vomiting and constipation.

DRUG INTERACTIONS: The central nervous system depressant effects of HYCOTUSS Expectorant may be additive with that of other central nervous system depressants. See WARNINGS.

Oral prescription where permitted by State law.

HYCOTUSS is an Endo registered U.S. trademark

6070-3BS

Endo Laboratories, Inc.
Subsidiary of the DuPont Company
Garden City, New York 11530

